March 1, 2019

Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB.

Platform, Trem-cel

Authored by: Olivier Humbert, PhD et. al. – Fred Hutchinson Cancer Research Center

Leukemia – 2019 Mar; 33(3):762-808